Recent Updates
Recently added Catalysts
NBIX Positive Sentiment Score: 75/100

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

Tuesday, March 17, 2026 1 min read
Key Takeaway: Neurocrine Biosciences has promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. In this role, he will oversee global technical development, manufacturing, and supply chain functions. This strategic move aligns with the company's goal to expand its portfolio beyond small molecules into biologics and device-based therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Andrew Ratz's promotion reflects the company's commitment to leadership.
  • The appointment supports Neurocrine's expansion into biologics and device-based therapies.
  • Dr. Ratz brings valuable experience to the executive management team.

Full Press Release Details

SAN DIEGO,March 17, 2026/PRNewswire/ --Neurocrine Biosciences, Inc.(Nasdaq:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies.

Frequently Asked Questions

Who has been appointed as the new CTO of Neurocrine Biosciences?

Andrew Ratz, Ph.D., has been promoted to Chief Technical Operations Officer.

What will Andrew Ratz oversee in his new role?

He will lead global technical development, manufacturing, and supply chain functions.

What is Neurocrine's focus with this appointment?

The company aims to expand beyond small molecules into biologics and device-based therapies.

When was the announcement made?

The announcement was made on March 17, 2026.

Tags: NBIX Viatris Investor Conferences Healthcare Neurocrine Biosciences Andrew Ratz Chief Technical Operations Officer biologics device-based therapies
Last updated: Mar 17, 2026